Evidence map›Paper›PMID 37284684›Full record

ArticleKidney international reports2023

Renal Function Underpins the Cyclooxygenase-2: Asymmetric Dimethylarginine Axis in Mouse and Man.

Plinio Ferreira, Ricky Vaja, Maria Lopes-Pires, Marilena Crescente, He Yu, Rolf Nüsing, Bin Liu, Yingbi Zhou, Magdi Yaqoob, Anran Zhang and 9 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 4 countries.

Plinio FerreiraNational Heart and Lung Institute, Imperial College London, United Kingdom.
Ricky VajaNational Heart and Lung Institute, Imperial College London, United Kingdom.
Maria Lopes-PiresNational Heart and Lung Institute, Imperial College London, United Kingdom.
Marilena CrescenteBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
He YuDeparment of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Rolf NüsingClinical Pharmacology and Pharmacotherapy Department, Goethe University, Frankfurt, Germany.
Bin LiuCardiovascular Research Center, Shantou University Medical College, Shantou, China.
Yingbi ZhouCardiovascular Research Center, Shantou University Medical College, Shantou, China.
Magdi YaqoobBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
Anran ZhangNational Heart and Lung Institute, Imperial College London, United Kingdom.
Matthew RickmanNational Heart and Lung Institute, Imperial College London, United Kingdom.
Hilary LonghurstDepartment of Medicine, University of Auckland, and Department of Immunology, Auckland City Hospital, Auckland, New Zealand.
William E WhiteBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
Rebecca B KnowlesBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
Melissa V ChanBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
Timothy D WarnerBlizard Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom.
Elizabeth WantDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Nicholas S KirkbyNational Heart and Lung Institute, Imperial College London, United Kingdom.
Jane A MitchellNational Heart and Lung Institute, Imperial College London, United Kingdom.
Imperial College London · GBQueen Mary University of London · GBShantou University · CNAuckland City Hospital · NZGoethe University Frankfurt · DEUniversity of Oxford · GB

Funding

British Heart Foundation FS/19/6/34129
6 · The paper itself

Abstract

Introduction: Through the production of prostacyclin, cyclooxygenase (COX)-2 protects the cardiorenal system. Asymmetric dimethylarginine (ADMA), is a biomarker of cardiovascular and renal disease. Here we determined the relationship between COX-2/prostacyclin, ADMA, and renal function in mouse and human models. Methods: We used plasma from COX-2 or prostacyclin synthase knockout mice and from a unique individual lacking COX-derived prostaglandins (PGs) because of a loss of function mutation in cytosolic phospholipase A Results: Loss of COX-2 or prostacyclin synthase in mice increased plasma levels of ADMA, citrulline, arginine, and cystatin C. ADMA, citrulline, and arginine positively correlated with cystatin C. Plasma ADMA, citrulline, and cystatin C, but not arginine, were elevated in samples from the patient lacking COX/prostacyclin capacity compared to levels in healthy volunteers. Renal function, ADMA, and citrulline were returned toward normal range when the patient received a genetically normal kidney, capable of COX/prostacyclin activity; and cystatin C positively correlated with ADMA and citrulline. Levels of ADMA and prostacyclin in conditioned media of kidney slices were not altered in tissue from COX-2 knockout mice compared to wildtype controls. Conclusion: In human and mouse models, where renal function is compromised because of loss of COX-2/PGI

Indexed as

ADMAkidneynitric oxideNSAIDprostacyclin

Identifiers

PMID37284684
PMCPMC10239776
OpenAlexW4360604174

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.